Gilead Sciences

Short interest in many of the leading biotech stocks shrank in the most recent period. Two stocks in particular stood out as leaders of that trend in those two weeks. Shares of one of those two stocks rose while the other slumped during the period. Short sellers moved on only a few of the leading...

A special report in this weekend's Barron's offers the results of the latest exclusive annual survey of companies with superior operating performance. See which drug wholesaler soared to the top of list for 2016. Other featured articles discuss the impending defeat of ISIS and the...

Short interest in many leading biotech stocks declined in the most recent period. Bucking that trend is a biotech company that soon will be acquired by an overseas peer. Short sellers retreated most sharply from a biotech that some analysts now see as a value stock. Between the March 31 and April...

The three largest biotechs are set to share their latest quarterly results this week. Wall Street analysts are looking for solid to strong growth from all three. However, expectations are lower for many other biotech and pharmaceutical companies reporting this week. The three largest public...

The cover story in this weekend's Barron's makes a case that the price of oil will bottom at $20 a barrel. Why a recovery in oil means a recovery in stocks is also discussed. Other featured articles focus on mutual funds, master limited partnerships and biotech companies. Oil could fall as low as...

Pharmaceutical giants Merck & Co., Inc. (NYSE: MRK) and Pfizer Inc. (NYSE: PFE) are expected to post quarterly results this week. Analysts are looking for different top and bottom line results from each. A few other pharmaceutical and biotech companies are on deck this week as well. Two of...

Last year was another banner one for U.S. dividend growth, but with higher interest rates in place and more rate hikes expected, S&P 500 dividend growth is anticipated to slow in 2016. Knowing that and following the struggles encountered by some dividend exchange-traded funds in 2015, income...

Short interest moves in leading biotech stocks were mixed in the most recent period. However, Illumina, Inc. (NASDAQ: ILMN) and Baxalta Inc (NYSE: BXLT) saw sharp increases in their short interest in late November. Short sellers appeared to lose interest in Juno Lighting LLC (NASDAQ: JUNO) late in...

It will be a busy week on the earnings front, with many blue chip companies reporting. Results from Apple are among the most highly anticipated and forecast to be strong. Expectations are also high for Alibaba, Gilead Sciences and JetBlue Airways. This week will be one of the busiest of the third...

Short interest changes in biotech stocks were mixed during the most recent period. Baxalta Inc (NYSE: BXLT) and Juno Therapeutics Inc (NASDAQ: JUNO) saw short interest surges in late September. Short interest in Medivation Inc (NASDAQ: MDVN) plunged during that time. With the ongoing market...

As market volatility continued after the August sell-off, short sellers moved on biotech stocks. Large cap biotechs Amgen, Celgene and Gilead Sciences saw surges in their short interest in early September. Short interest rose in nearly all of the leading biotech stocks in that time. With the...

Between the July 31 and August 14 settlement dates, the number of shares short in the leading biotech and emerging pharmaceutical stocks was mixed. Short sellers were especially drawn to Biogen Inc (NASDAQ: BIIB), Gilead Sciences, Inc. (NASDAQ: GILD) and Vertex Pharmaceuticals Incorporated (...